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Abstract 
Introduction:  
The purpose of this paper is to clearly define conservative (non-dialytic) kidney care and 
report the current evidence in relation to conservative management.  
Definition:  
Comprehensive conservative care is widely recognized and delivered, but until recently has 
not been clearly defined. This paper provides a clear definition of comprehensive conservative 
care. This includes interventions to delay progression of kidney disease and minimize 
complications, as well as detailed communication, shared decision-making, advance care 
planning, psychological and family support. It does not include dialysis. 
Prevalence:  
Limited epidemiological evidence from Australia and Canada indicates that for every new 
person diagnosed with end-stage kidney disease who receives dialysis or transplant, there is 
one new person that is managed conservatively (either actively or not).  
Survival: 
For older patients (those over 75 or 80 years) who have higher levels of co-morbidity (such as 
diabetes, heart disease) and poorer functional status, the survival advantage of dialysis may 
be limited, and comprehensive conservative management may be considered. Robust 
comparative evidence remains limited, however. 
Symptoms and quality of life:  
Considerations of symptoms, quality of life, and hospital-free days are as or sometimes more 
important for patients and families than survival. There is some evidence that communication 
about possible conservative management options is generally insufficient, even where 
comprehensive conservative care pathways are already established. Symptom control and 
the cost-effectiveness of interventions are addressed in the companion papers within this 
series. 
Future research: 
There is almost no evidence about which models of care and which interventions might be 
most beneficial in this population; future research on these areas is much needed. 
Meanwhile, consistency in definition of comprehensive conservative care, and basing 
interventions on existing evidence about survival, symptoms, quality of life, and experience 
will maximize patient-centred and holistic care.  
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Introduction 
The purpose of this paper is to clarify the definition of conservative (non-dialytic) care of 
end-stage kidney disease, and report the evidence on prevalence, survival, symptoms, 
quality of life and illness experience in relation to conservative management. It also 
delineates the implications of this evidence for clinical care and for research.  
 
Defining conservative care 
Conservative (non-dialytic) kidney care is widely recognized and delivered, but until recently 
has not been clearly defined. The Renal Physicians Association Shared Decision-Making 
Guideline uses the term ‘active medical management without dialysis’ (1) (2). A range of 
alternative terms, such as conservative care, maximal conservative management, renal 
supportive care, palliative care, or supportive care, have been used in relation to non-dialysis 
care in end-stage kidney disease, but without clear definition. This has constrained 
recognition of the health-care needs of this sector of the end-stage kidney disease population, 
and has prevented systematic study to build evidence on ways to best improve care and 
outcomes. The occasional use of the terms ‘palliative care’ or ‘supportive care’ as synonymous 
with non-dialytic care is particularly misleading, as palliative and supportive care can be 
provided alongside dialysis as well as conservative care.  
 
Box 1: Definition of comprehensive conservative care 
‘Comprehensive conservative care’ is planned holistic patient-centred care for patients with 
Stage 5 (glomerular filtration rate category 5) Chronic Kidney Disease that includes: 
 • Interventions to delay progression of kidney disease and minimize risk of   
       adverse events or complications 
 • Shared decision making 
 • Active symptom management 
 • Detailed communication, including advance care planning 
 • Psychological support 
 • Social and family support 
 • Cultural and spiritual domains of care 
Comprehensive conservative care does not include dialysis. 
From the Kidney Disease | Improving Global Outcomes (KDIGO) Controversies Conference 
on Supportive Care in Chronic Kidney Disease (3)  
 
To counter this, a recent consensus conference (3) proposed a detailed, specific definition for 
conservative care in end-stage kidney disease, suggesting adoption of the term 
‘comprehensive conservative care’ to reflect the full extent of conservative management, and 
providing a full definition (see Box 1) of what comprehensive conservative care should 
include. The conference also proposed three distinct groups within the conservative care 
population (see Box 2), to address concerns about availability of renal replacement therapy 
and options for choice across the spectrum of low-, middle-, and high-income countries. 
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Box 2: Distinct conservative care populations 
1. Comprehensive conservative care. Conservative care that is chosen or medically advised. 
2. Choice-restricted conservative care. Conservative care for patients in whom resource 
constraints prevent or limit access to renal replacement therapy; therefore, a choice for 
conservative care cannot be recognized. 
3. Unrecognized Stage 5 (glomerular filtration rate category 5) chronic kidney disease. Chronic 
kidney disease is present but has not been recognized or diagnosed; therefore, a choice for 
conservative care cannot be recognized. 
From the Kidney Disease | Improving Global Outcomes (KDIGO) Controversies Conference 
on Supportive Care in Chronic Kidney Disease (3) 
 
How common is conservative care? 
 
One of the first considerations is understanding the size of the population of those with end-
stage kidney disease who are managed conservatively. There is very limited evidence on the 
incidence or prevalence of conservative care of end-stage kidney disease, and population-
based needs assessments in relation to conservative care are rare. In 2011, a detailed whole 
population-based study was published in Australia to estimate the total incidence of end-
stage kidney disease (4), including (for the first time) both those treated with renal 
replacement therapy and those receiving conservative care. Previous evidence on end-stage 
kidney disease from the national and international Renal Registries has been limited to those 
with dialysis or transplant. The authors identified 21,500 new cases of end-stage kidney 
disease in Australia during the period 2003 – 2007  (4); this amounted to 21 cases per 100,000 
people (20.9 per 100,000 population, with 95% confidence intervals of 18.3 – 24.0 per 
100,000 population). For every new case who received dialysis or transplant, there was about 
one new case that did not.   
 
A community-based cohort study in Canada demonstrated that, during median follow-up of 
4.4 years of 1,816,824 adults with measured eGFR in Alberta, Canada, 5.36% died, with 0.18% 
who developed kidney failure that was treated and 0.17% who developed kidney failure that 
was managed conservatively (5). As in the Australian population based study  (4), for every 
new case who received dialysis or transplant, there was about one new case that did not, and 
rates of untreated kidney failure were consistently higher at older ages. Both studies indicate 
that the incidence of advanced kidney disease in older people may be higher than previously 
thought, and certainly there are greater than expected rates of untreated kidney failure 
among the oldest patients. It may be that further population-based studies in other countries 
would show similarly higher than expected levels of conservative management of end-stage 
kidney disease.  
 
In interpreting these findings, there are some major limitations. First, national data is only as 
yet available from Australia and Canada, and may not apply to other countries and contexts. 
Secondly, just as dialysis patterns have changed over time, so it is probable that patterns of 
conservative care have changed over time. It is worth noting that in the Australian whole 
population-based study, neither the overall proportion of new cases managed with 
5 
 
conservative care nor the age standardized rate of conservative care consistently changed 
over time period 2003 – 2007, but this is a relatively short timeframe, and further study across 
more extended time periods is needed. Thirdly, and perhaps most important of all, this data 
relates only to high income countries; the limited availability of dialysis in some low- and 
middle-income countries may have a profound impact on the apparent prevalence of 
‘conservative management’, and underlines the importance of defining and understanding 
the different sectors of the population who are managed without dialysis (as defined in Box 
2). 
 
 
What is the evidence on survival in conservative care? 
 
A further consideration is survival of those managed without dialysis. One of the main 
challenges in studying and comparing survival between dialysis and conservative populations 
is the bias inherent in the pathway decision. Those who are more fit usually opt for dialysis, 
and many choose or are advised to have conservative management because of co-morbidity 
or other factors which in themselves adversely influence survival. Without randomization into 
either group, it is difficult to attribute survival differences to either dialysis or conservative 
management.  
 
Recent changes in dialysis practice, with lowering of the average eGFR for starting dialysis 
following the Initiation of Dialysis Early And Late (IDEAL) trial (6), mean that lower starting 
eGFR to base comparative estimates of survival and quality of life between dialysis and non-
dialysis treatment pathways may be more feasible.  We also need improved understanding of 
renal progression risk (particularly in older patients with low eGFR without proteinuria), to 
determine those least likely to benefit from dialysis.  
 
In addition, many studies do not compare survival, hospital days and symptoms, or quality of 
life between the two populations; any meaningful comparison needs to consider not only 
survival, but also the nature of any additional days of survival. Days spent attending or in 
hospital, or with poor quality of life are not rated as highly by patients as hospital-free days, 
and days with good quality of life  (8) (9). 
 
The key evidence on survival of patients managed conservatively can be distilled from 
fourteen studies (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23). These are 
excellently summarized in the systematic review by O’Connor (24), with later studies by Silva 
Gane et al (20) and Hussain (23). In the absence of randomized controlled trials (ethically and 
practically difficult, if not impossible), each of these studies is flawed in one way or another.  
Only about half (11) (12) (15) (16) (18) (19) (20) (23) compare survival between conservative 
patients and those on dialysis. The main flaws relate to significant differences in the 
comparison groups with regard to age profiles, how conservative/dialysis decisions were 
made, varying time from which survival is measured(including computing or assuming actual 
or putative ‘dialysis start’ dates), likely changes in referral and dialysis practices over recent 
decades, and the reality that it is only truly legitimate to compare survival outcomes when 
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each group is eligible for both treatment options (25). Some studies provide further context 
for the end-stage kidney disease and report co-morbidity or level of 
dependence/performance but scoring systems vary and the Charlson score in particular may 
"double count” or over-score age. In contrast, frailty - which is very common in this population 
and independently associated with increased mortality - is rarely measured or reported (26).  
 
An additional challenge is that the conservative care population is heterogeneous. It includes 
at least three groups of patients whose survival is likely to be very different; first, those 
suitable for dialysis who choose not to receive it, second, older people with high co-morbidity 
where dialysis is not offered, and third, patients who lack capacity and may not always be 
offered dialysis. Although some of the studies try to make these distinctions, the numbers in 
the conservative management arms are often small and difficult to analyze with precision.  In 
France, a multicenter prospective cohort study of 581 older patients (mean age 82 years) with 
end-stage kidney disease has shown that, despite a high prevalence of comorbidities, most 
patients are autonomous and living at home. At inclusion, 43% postponed the dialysis decision 
due to stable estimated glomerular filtration rate, 17% were under evaluation, 24% chose 
dialysis, and 16% decided not to have dialysis (27). Szeto et al present data on 25 patients 
who were considered suitable for but declined dialysis; and contrasted this group with 38 
patients who were not considered suitable for dialysis, mainly because of multiple co-existing 
medical illnesses. The former ‘declining group’ were younger and less co-morbid than the 
latter group, and yet had no difference in survival (22). Another confounder is that most 
studies do not address survival advantage/excess mortality of patients, in relation to life 
expectancy of age-matched period-specific individuals in the general population.  
 
Among the key survival studies, the work by Joly studying those 80 years and over (11) is 
notable for long follow up (up to 12 years) so that differences in referral patterns could be 
sought over different time periods. Those not put forward for dialysis were of similar age but 
were more likely to be socially isolated, referred later, diabetic, and have poorer 
performance.  Survival was significantly longer in the dialyzed group (28.9 versus 8.9 months). 
Usefully, the 2.4 year life expectancy of the dialyzed octogenarians was related to population 
norms, and represented about one quarter to one third of the life expectancy of the general 
population over 80 years as reported in national life expectancy statistics in France at the 
time.  In contrast, the most widely cited paper of Smith et al (12) is based on very small 
numbers (10 and 26 respectively), comparing those recommended not to dialyze who 
nevertheless decided to dialyze, and those who followed the recommended conservative 
pathway. Their finding of no significant survival advantage (8.3 months versus 6.3 months) 
between these frail elderly patients was important despite the small numbers, and despite 
the fact that a putative dialysis initiation date was based on eGFR of <10 ml/min estimated 
using the Cockroft-Gault formula.  In this study, 65% of the deaths occurring in the dialyzed 
patients took place in hospital compared with 27% in the conservative group (used as a 
surrogate quality indicator). 
 
Carson (18) attempted to “start the clock” at an equivalent time in the comparative groups 
(all incident patients 70 years and older) by computing ‘putative’ dialysis start times (e-GFR 
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10.8ml/min/m2) which mirrored practice in the dialysis group (18).  They showed significant 
survival advantage in the dialyzed group (37.8 versus 13.9 months), but the conservative 
group were approximately 10 years older; statistical corrections could not be made to correct 
for this age difference because of the small numbers.  The conservative patients were more 
likely to die at home or in a hospice (again, used as an indirect quality marker) and the authors 
computed that every day of additional survival was almost at the expense of a day spent 
either as an inpatient or attending hospital for dialysis (hospitalization 0.069 versus 0.043 
hospital days per patient days survived) (18).  A different approach was adopted by Murtagh 
et al, who measured survival from estimated GFR < 15 mL/min (15). They confined their 
analysis to all those with Stage 5 chronic kidney disease over 75 years known to nephrology 
clinic. Once again, the overall survival was better in the dialysis group but this advantage was 
lost in patients with high comorbidity.  There are a number of caveats to this study. No ‘late 
presenters’ were included (so this may not reflect real life practice and cannot be compared 
with studies where all incident patients are included).  The age of the conservative group was 
4 years older than the dialysis group, and perhaps most importantly, the analysis was on an 
‘intention to treat’ basis. 24 patients (24/52) who chose the dialysis pathway did not actually 
receive dialysis by the study end either because they died (n= 8) or because dialysis had not 
yet started (n= 16).  
 
Szeto reported on survival of 63 conservative patients, and while these authors did not 
attempt to compare conservative and dialysis groups, they do (like Carson et al) provide useful 
data on the sub-group who declined dialysis (n= 25) (22). These were on average a decade 
younger and had much lower co-morbidity scores but – importantly - their survival was not 
significantly different from the conservative group. The median survival from the date of 
needing dialysis (7mls/min) was 6.58 months. Of note also only 36/63 were deemed to have 
died from uraemia, with other unrelated deaths occurring both before (n= 12) and after the 
theoretical date of needing dialysis (n=7).  Taking this study and inferring from other studies 
(11) (12) (18), there is fair evidence that the median survival from e-GFR 6-7 ml/min is around 
6 months.  
 
The more recent papers (19) (23) offer the best available evidence on survival.  Work by 
Chandna and colleagues spans an 18 year period and involving 844 patients, 155 (18%) of 
whom received conservative care (19).  Conservative patients were older and had higher co-
morbidity.  Again there was an overall survival advantage to dialysis (mean survival 21.2 
versus 67.1 months p<0.001).  However (as earlier studies had indicated, but less robustly), 
for patients over 75 years the survival advantage of dialysis reduced to only 4 months (non-
significant) when corrected for age, high co-morbidity and diabetes. Similarly, in a 
retrospective observational study of patients over the age of 70 years attending pre-dialysis 
clinic comparative survival, Hussain reported hospital admission and palliative care access 
outcomes between patients managed conservatively or choosing renal replacement therapy 
(23).  Survival, measured from three time points for both groups (e-GFR was <20mL/min, <15 
mL/min and <12 mL/min), showed that dialysis conferred a significant survival advantage.  
However, there was a significant reduction in the effect of dialysis pathway on survival for 
those with high Charlson comorbidity index.  Hospital admissions were greater and chances 
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of dying at home were less in the dialysis patients. There was no survival advantage from 
dialysis in the >80 year olds with high co-morbidity or poor functional status at all levels of 
disease severity.  
 
 
What about symptoms, quality of life and illness experience in conservative care? 
 
It is not only survival that is important, but crucially the symptoms, quality of life and 
experience of illness on the conservative management pathway (8). Once again there is 
limited evidence. O’Connor’s systematic review provides the best summary of evidence about 
symptoms and quality of life (24).  Six studies describe symptom burden and/or quality of life.  
Most are cross sectional in design and all received a level 2 - or intermediate - strength of 
recommendation taxonomy rating in the review (24) (28).  Three studies used the Memorial 
Symptom Assessment Schedule to collect data (29) (30) (31), while one study used a modified 
POSs (32). Three articles directly measured quality of life (16) (31) (33), using standardized 
tools (either the Short Form 36 Health Survey Questionnaire, or the EuroQoL EQ5D survey). 
One study also used interviews (16) .  
 
All report significant symptom burden in those undergoing conservative care, with numbers 
of symptoms varying from 6.8 to 17 per individual patient.  These studies were remarkably 
consistent in terms of reporting similar symptoms and similar patterns of prevalence.  Where 
reported, there was a considerable increase in symptoms in the month prior to death (30). 
Evidence on management of symptoms is included in (cross reference to this paper in series). 
Three of the studies (16) (31) (33) included a comparison group. Since the systematic review 
of this evidence, Da Silva Gane and colleagues have published further evidence reporting 
quality of life assessments every three months for up to three years in patients with advanced, 
progressive chronic kidney disease (late stage 4, early stage 5) managed conservatively or by 
dialysis (20).  This is the only longitudinal study which contrasts conservative and dialysis 
management; conservative patients were older, more dependent and more highly comorbid 
with poorer physical health and higher anxiety levels than dialysis patients.  Their most 
important finding however was that the conservative patients maintained quality of life, while 
life satisfaction decreased significantly after dialysis initiation in the dialysis group. Mental 
health, depression, and life satisfaction scores were overall similar in the two groups at the 
start of the study. Brown and colleagues have also reported survival, symptom burden, and 
quality of life in conservatively-managed patients (7), including 273 pre-dialysis patients who 
had usual nephrology care and 122 non-dialysis pathway patients who also attended a renal 
supportive care clinic. Median survival in the latter group was 16 (interquartile range, 9, 37) 
months. With the renal supportive care clinic input, 57% of the non-dialysis patients had 
stable or improved symptoms over 12 months and 58% had stable or improved QOL.  
 
Although O’Connor and colleagues have proposed that additional head to head studies are 
needed to compare the symptoms of age-matched dialysis patients, they also felt that the 
current available studies suggested that quality of life was not significantly different in 
conservative patients as in dialysis patients (24). The more recent work by Da Silva Gane and 
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colleagues confirms this, and the work by Brown et al suggests that renal supportive care 
clinics can be effective in controlling symptoms and maintaining quality of life, although the 
specific interventions need further study.   
 
Beyond physical and psychological symptoms and quality of life, spiritual care needs have also 
been considered, although critically, in all advanced kidney disease patients rather than 
specifically in the conservative population. In a prospective cohort study of 253 stage 4 and 5 
chronic kidney disease and dialysis patients in Canada, patients reported a mean of 2.9 ± 2.6 
spiritual needs, with 69% of patients reporting at least one spiritual need. 32% of patients had 
high spiritual needs (defined as reporting ≥ 5 of the seven needs). Spiritual needs were 
associated with age, gender, race, marital status, dialysis modality, time on dialysis, or 
comorbidity (34). A further study using the same cohort found that adjustment in the domains 
of psychological distress and extended family relationships appears to mediate some of the 
beneficial effect of existential well-being on health-related quality of life. Spirituality, 
however, provides unique variance in patients' quality of life, independent of their 
psychosocial adjustment (35).  
 
A final piece of important evidence relates to the impact on family of caring for someone with 
chronic kidney disease stage 5. Work undertaken in the United Kingdom (36) investigated this, 
and identified confusion about the nature of conservative kidney management. Carers were 
not aware of the palliative nature of conservative care or the approaching end-of-life issues, 
and this highlighted some of their unmet support needs. This resonates with evidence directly 
from patients themselves; that patients' expectations of conservative care are strongly 
influenced by what is communicated to them by renal staff (37). Even in renal units with 
established conservative care pathways, there is often only limited information available to 
patients and families about illness progression and what to expect as the illness progresses. 
  
Conclusion 
 
Evidence on conservative care remains limited. The best evidence is on survival; this does not 
necessarily reflect what matters most to patients with end-stage kidney disease and their 
families; instead it reflects what has been studied to date.  The published comparative survival 
outcomes between dialysis and conservative management suffer from inherent 
methodological flaws which limit any conclusions.  
 
There is no doubt that – in general - dialysis is associated with a significant survival advantage, 
but this advantage reduces notably for older people with major co-morbidity and poorer 
functional status, with little or no survival benefit for older people (over 75 years), with high 
co-morbidity scores, and poor functional status. Quality of life, symptoms, and hospital-free 
survival may be at least as important to consider and actively manage. Before starting kidney 
replacement therapy, there should be a shared decision-making process based on 
understanding of prognosis, the potential benefits and harms of therapy, and patient values, 
goals, and preferences (38). It is not yet known which the best models of care or interventions 
are for those managed conservatively without dialysis. The limited evidence on cost-
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effectiveness is summarized in (cross reference to this paper in series), but further study of 
best ways to improve and maintain quality of life, as well as survival, are needed. 
 
The perspectives on comprehensive conservative care may vary between countries, according 
to the availability of renal replacement therapy – this is important, and characterizing the 
different conservative care populations can help. However, there is consensus on how 
comprehensive conservative care can be defined, and what it includes, and adopting this 
definition and consistency in what is delivered will help to support service development and 
future research. The use of a standard definition will provide both clinicians and researchers 
a framework for moving the field forward.    
 
Research now needs to incorporate changes in dialysis practice, with comparative studies of 
survival and quality of life allowing for the lower average eGFR of dialysis start.  We need 
improved evidence about renal progression risk, to further determine those least likely to 
benefit from dialysis. While there is clear evidence of symptom burden and poor quality of 
life in conservative management, the interventions and models of care which best address 
these issues are yet to be determined; this research must be addressed from patient and 
family perspectives if it is to deliver greatest impact. 
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